Roivant Sciences Ltd. (ROIVW) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は London, イギリス. 現CEOは Matthew Gline.
ROIVW を有する IPO日 2021-09-27, 620 名の正社員, に上場 NASDAQ Global Market, 時価総額 $1.97B.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
